Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

versus placebo plus bendamustine and rituximab in subjects with newly diagnosed MCL, SHINE (MCL3002).
- A Phase II single-arm study of ibrutinib as a monotherapy in patients with MCL who received at least one prior rituximab-containing chemotherapy regimen and who progressed after bortezomib therapy, SPARK (MCL2001).
- A Phase II single-arm study of ibrutinib as monotherapy in patients with relapsed or refractory MCL (PCYC-1104).

Conference Call
Further updates will be provided during the upcoming quarterly conference call on February 14, 2013 at 4:30 p.m. EDT. To participate in the conference call, please dial 1-877-407-0778 for domestic callers and 1-201-689-8565 for international callers. To access the live audio broadcast or the subsequent archived recording, log on to http://ir.pharmacyclics.com/events.cfm. The archived version of the webcast will be available for 30 days on the Investor Relations section of the company's Web site at http://www.pharmacyclics.com.

About Mantle Cell Lymphoma
MCL is an aggressive type of B-cell non-Hodgkin lymphoma (NHL) that usually occurs in older adults. The disease typically begins in the lymph nodes but can spread to other tissues, such as bone marrow and liver. Ibrutinib targets the B-cell receptor pathway an important pathway in malignant B-cell growth and proliferation. In the United States there are approximately 5,000 new cases of MCL each year.

About Waldenstrom's macroglobulinemia
Waldenstrom's macroglobulinemia is rare type of lymphoma. The disease begins with a malignant change to the B-cell during its maturation so that it continues to reproduce more malignant B-cells resulting in an overproduction of monoclonal immunoglobulin M antibody (IgM). WM is a hematologic malignancy for which no established standard of care - or approved therapeutic exists. I
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... 2015  Profil Institute for Clinical Research, Inc., a clinical ... today a new textbook,  Translational Research Methods for Diabetes, ... leading global scientific publisher. The textbook is ... use in early phase clinical studies of new drugs ...
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/w25xpc/allergy ) has announced the addition of ... by End User - Global Forecast to 2019" report ... market is valued at $1,228.58 million in 2014 and is ... $2,230.72 million by 2019. Allergy diagnostics is used to determine ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 2Global Allergy Diagnostics (Immunoassay Analyzer, Luminometer, Assay Kit, Consumables) Market - Forecast to 2019 3
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... following a final approval from the US Food ... New Drug Application (ANDA) for generic Acular® opthalmic ... This strength of ketorolac is therapeutically equivalent to ...
... Althea Technologies, Inc., a leading provider of ... the addition of customized Formulation Development to the ... by the newly appointed Dr. James Matsuura, Director ... team of formulation and analytical scientists, along with ...
Cached Medicine Technology:Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Juvent Sports ... at the 2015 PGA Merchandise Show to bestow a ... incredible female amateur golfer, Arlene McKitrick. The award commemorated ... amateur golf tournament win. She won her first amateur ...
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Joan Lunden, ... keynote speaker at the upcoming 32nd Annual Miami ... Physicians’ Education Resource®, LLC (PER®) , shares that ... have gone undetected if she had not followed up ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... kidney transplant recipients need to take immunosuppressive drugs for the ... the thousands who have undergone transplantation, have been able to ... studying these rare individuals have identified a pattern of genes ... day be used to help identify other transplant recipients who ...
... about beta blockers making COPD worse are unfounded, experts ... tradition says that the beta blockers used to treat ... have severe lung disease, but a new Dutch study ... more than 2,200 people with chronic obstructive pulmonary disease ...
... ... President and Chief Executive Officer, is a finalist for the Ernst & Young Entrepreneur of ... ... Pentec Health Incorporated announced today that Joe Cosgrove, President and Chief Executive Officer, is ...
... Medicine for the first time have determined that bone marrow ... the bone marrow a potential therapeutic target, especially in people ... of the respiratory tract, cells produced by the bone marrow ... help fight infection. The data are published in the current ...
... University ... Mind Project. The Developing Mind Project aims to discover fundamentals of early learning and ... ... Learning & Brain Sciences (I-LABS) today announced the launch of a multi-year, multimillion-dollar initiative ...
... ... offered leadership and guidance about the transition from paper to electronic medical records for ... was held in mid-May. , ... Dearborn, MI (Vocus) May 24, 2010 -- Secure-24 and ATMP offered leadership ...
Cached Medicine News:Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 2Health News:Gene pattern may identify kidney transplant recipients who don't need lifelong anti-rejection drugs 3Health News:Heart Drugs Safe for Lungs, Study Finds 2Health News:Heart Drugs Safe for Lungs, Study Finds 3Health News:Joseph Cosgrove Named as E&Y Entrepreneur Of The Year Finalist in the Greater Philadelphia Region 2Health News:Joseph Cosgrove Named as E&Y Entrepreneur Of The Year Finalist in the Greater Philadelphia Region 3Health News:Mount Sinai discovers bone marrow plays critical role in enhancing immune response to viruses 2Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 2Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 3Health News:University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project 4Health News:ATMP and Secure-24 Offer Physicians Leadership and Guidance for Electronic Medical Records 2Health News:ATMP and Secure-24 Offer Physicians Leadership and Guidance for Electronic Medical Records 3
... The NOW® Malaria Test is a field or ... Malaria infection. It is intended for the detection ... and an antigen that is common to all ... (P.f.), Plasmodium vivax (P.v.), Plasmodium ...
... Central Station provide an example of the ... cath or electrophysiology lab to healthcare professionals ... providing both physiomonitoring parameters and electronic charting ... on its own network. Witts Central Station ...
For the critical care environment, telemetry, emergency room and other monitoring areas....
DS 7600 Central Station...
Medicine Products: